MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

CU-CPT22

CAS No. : 1416324-85-0

MCE 站：CU-CPT22

产品活性：CU-CPT22 是一种有效的 toll 样受体 1 和 2 (TLR1/2) 蛋白复合物抑制剂，可与 TLR1/2 结合的合成三酰脂蛋白 (Pam₃CSK₄) 竞争，K_i 值为 0.41 ?M。 CU-CPT22 阻断 Pam₃CSK₄ 诱导的 TLR1/2 激活，IC₅₀ 值为 0.58 ?M。

研究领域：Immunology/Inflammation

作用靶点：Toll-like Receptor (TLR)

In Vitro: CU-CPT22 is a toll-like receptor 1 and 2 (TLR1/2) inhibitor with an IC₅₀ of 0.58±0.09 ?M. It is demonstrated that CU-CPT22 is able to compete with Pam₃CSK₄ for binding to TLR1/2 with an inhibition constant (K_i) of 0.41±0.07 ?M, which is consistent with its potency observed in the whole cell assay. Increasing the concentration of CU-CPT22 to 6 ?M decreases the anisotropy to background levels. It is found that CU-CPT22 inhibits TLR1/2 signaling without affecting other TLRs, showing it is highly selective in intact cells. CU-CPT22 is found to have no significant cytotoxicity at various concentrations up to 100 ?M in RAW 264.7 cells. The result demonstrates that CU-CPT22 can inhibit about 60% of TNF-αand 95% of IL-1β at 8 ?M.

相关产品：Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Anti-Cancer Compound Library  |  Small Molecule Immuno-Oncology Compound Library  |  Antioxidants Compound Library  |  Differentiation Inducing Compound Library  |  Oxygen Sensing Compound Library  |  Pyroptosis Compound Library  |  Chloroquine  |  Resatorvid  |  Resiquimod  |  Hydroxychloroquine sulfate  |  C29  |  Imiquimod  |  Sulfo-ara-F-NMN  |  Polyinosinic-polycytidylic acid sodium  |  CU-T12-9  |  MD2-IN-1  |  Schaftoside  |  TH1020  |  IAXO-102  |  CU-CPT-8m  |  Atractylenolide I  |  TLR7/8 agonist 1 dihydrochloride  |  DSR-6434  |  TLR4-IN-C34  |  Sparstolonin B  |  Isofraxidin  |  Procyanidin B1  |  CU-CPT17e  |  Robinin  |  Loxoribine  |  CL075  |  FSL-1 TFA  |  Okanin  |  Polygalasaponin F

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。